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Abstract
Background: Human mast cell (HuMC) maturation occurs in tissues interfacing with the external
environment, exposing both mast cell progenitors and mature mast cells, to bacteria and their
products. It is unknown, however, whether long- or short-term exposure to bacteria-derived toll-
like receptor (TLR) ligands, such as lipopolysaccharide (LPS) or peptidoglycan (PGN), influences
HuMC biology.
Results: Over 6 wks of culture, LPS had minimal effect on HuMC numbers but increased CD117,
tryptase and chymase expression. PGN inhibited HuMC development. For mature mast cells, LPS
in the presence of rhSCF (10 ng/ml) increased CD117, tryptase, chymase and carboxypeptidase
expression, primarily in CD117low HuMC. LPS decreased FcεRI expression and β-hexosaminidase
release; but had no effect on LTC4 and PGD2 production. PGN reduced HuMC numbers; and
CD117 and tryptase expression. IL-1β and IL-6 (in addition to IL-8 and IL-12) were detected in
short-term culture supernatants of LPS treated cells, and reproduced the increases in CD117,
tryptase, chymase, and carboxypeptidase expression observed in the presence of LPS. Comparative
studies with mouse bone marrow-derived mast cells from wild type, but not TLR4 knockout mice,
showed increases in mRNA of mouse mast cell chymases MMCP-1, MMCP-2 and MMCP-4.
Conclusion: PGN inhibits HuMC growth, while LPS exerts its primary effects on mature HuMC
by altering cytokine production and protease composition, particularly at low concentrations of
SCF. These data demonstrate the ability of bacterial products to alter HuMC mediator production,
granular content, and number which may be particularly relevant at mucosal sites where HuMC are
exposed to these products.
Background
Human mast cells (HuMC) originate from bone marrow-
derived CD34+  pluripotent progenitor cells [1] and
migrate as immature cells from the bone marrow to tissue
sites including the lung and gastrointestinal tract. There
they mature and participate in both innate and acquired
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immune responses with production of cytokines and
other inflammatory mediators [2]. Mast cell growth and
development thus may occur in a tissue that interfaces
with the external environment, potentially exposing
HuMC during their development to bacterial products
which could have an impact on their subsequent behav-
ior. Consistent with this idea is the observation that
HuMC have been shown to express Toll-like receptors
(TLR) 1–7, and 9 both in vitro and in vivo (lung) [3]; and
exposure to such bacterial products as endotoxin
(lipopolysaccharide; LPS) or peptidoglycan (PGN) leads
to expression and release of TNF-α, GM-CSF, IL-1, IL-5, IL-
10, IL-13 and IL-15 [4-6]. However, and in a related ques-
tion, it is currently not known whether bacteria-derived
products alter the growth and development of HuMC.
We therefore asked whether long or short-term exposure
to LPS and PGN could alter specific HuMC characteristics
including growth; surface FcεRI and CD117 expression;
and β-hexosaminidase, LTC4 and PGD2 release; protease
expression and composition, and cytokine release. As will
be shown, LPS augmented protease expression and altered
protease composition in developing and mature HuMC,
while reducing FcεRI expression and IgE-mediated
degranulation. This effect in short-term cultures was
mediated through HuMC release of IL-1β and IL-6. PGN
inhibited HuMC growth at all concentrations studied.
Results
Effect of LPS and PGN on progenitor HuMC in 6 wk (long-
term) cultures
To determine the effect of LPS or PGN over 6 wks on
HuMC growth and development, 10–1000 ng/ml LPS or
10–1000 μg/ml PGN was added to CD34+ cultures con-
taining 100 ng/ml rhSCF. Kimura's staining of metachro-
matic positive HuMC correlated with tryptase staining of
HuMC granules on cytopreparations, did not differ by
greater than 5%, and was used for counting small num-
bers of HuMCs available to study, with minimal cell loss.
As shown in Figure 1A, incubation of CD34+ cells with
SCF alone resulted in increased total cell numbers by 3
wks which then gradually declined by 6 wks, while HuMC
numbers rose steadily from 2–4 wks and were sustained
up to 6 wks, by which time all cells in culture were HuMC.
The addition of LPS to CD34+ cells over 6 wks of culture
had no effect on total cell or HuMC numbers (Fig. 1B). In
contrast, PGN initially increased total cell numbers by 1–
3 wks, but this increase was short lived, and total numbers
rapidly declined after 2–3 wks (Fig. 1C). HuMC growth
was totally suppressed by PGN at 1000 μg/ml while PGN
at 100 μg/ml suppressed HuMC growth by 3 wks. HuMC
were seen in culture in the presence of 10 μg/ml PGN, but
numbers were less than half of numbers seen with rhSCF
alone (Fig. 1C; compare with 1A). Inhibition of HuMC
growth was also seen with another TLR2 agonist, lipotei-
choic acid (LTA). As seen in Figure 1D, LTA at 1.0–10 μg/
ml decreased total cell numbers starting at 2–3 wks. The
addition of LTA at 1.0–10 μg/ml suppressed HuMC
growth beginning at 3–4 wks and for the duration of the
cultures (Fig. 1D; compare with 1A). Thus, the addition of
LPS over 6 wks did not alter HuMC numbers while PGN
and LTA inhibited HuMC outgrowth.
Effect of LPS and PGN on 8 wk old HuMC CD117 and 
FcεRI expression in 72 hr (short-term) cultures
We next reasoned that exposure to LPS or PGN would
occur to more mature mast cells in some situations and
promote HuMC differentiation. We thus cultured mature
8 wk old HuMC in either 100 ng/ml or 10 ng/ml rhSCF in
the presence or absence of 100 ng/ml LPS or 10 μg/ml
PGN (selected on the basis of long term culture results)
for 72 hrs. Cells were then counted, harvested and exam-
ined by flow cytometry for FcεRI and CD117 expression.
LPS 100 ng/ml or 10 ng/ml PGN had no effect on HuMC
numbers when cultured in combination with rhSCF 100
ng/ml for 72 hr. When rhSCF was reduced to 10 ng/ml
(Fig. 2A), HuMC numbers decreased consistent with less
rhSCF in the cultures. Viability of the remaining HuMC
after 72 hrs ranged from 90–95%. The added presence of
LPS increased HuMC numbers after 72 hrs as compared
with rhSCF alone (n = 3, p < 0.01), while PGN again
resulted in fewer HuMC in culture (n = 3, p < 0.01). The
addition of either 10 μg/ml PGN or 10 μg/ml LTA caused
an increase of approximately 27% and 55%, respectively,
of apoptotic cells compared to cultures in 10 ng/ml rhSCF
alone, in contrast to 100 ng/ml LPS which reduced apop-
tosis by approximately 50%. To eliminate cell debris or
any monocytes from being analyzed, CD117+/FcεRI+
HuMC were gated, followed by examination for other sur-
face markers or intracellular proteases. As shown in Figure
2B, in the presence of 100 ng/ml rhSCF, a homogeneous
population of CD117+/FcεRI+ HuMC was seen (approxi-
mately 70%). In the added presence of 100 ng/ml LPS,
CD117+/FcεRI+ cells decreased by approximately 7% for
HuMC, with a concurrent decrease in FcεRI expression
(right lower quadrant). Reducing the concentration of
rhSCF to 10 ng/ml for 72 hrs (Fig. 2C) gave rise to two dis-
tinct HuMC CD117+  subpopulations: CD117low  (open
arrows) and CD117high (solid arrows), with a log-fold
increase in MFI for CD117high cells as compared with cul-
tures using 100 ng/ml rhSCF alone (Fig. 2C inserts). The
addition of 100 ng/ml LPS over 72 hrs to CD117low and
CD117high  HuMC maintained in 10 ng/ml rhSCF
decreased FcεRI expression on CD117+/FcεRI+ cells (right
lower quadrant) by approximately 9%. Histochemical
examination of CD117high and CD117low cells confirmed
that both populations shared characteristics, such as
numerous surface projections, large and irregular nuclei,
and abundant cytoplasmic granules, consistent with cul-
tured HuMC, as described [7]. Thus, FcεRI+ expression onBMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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Cultures of CD34+ derived HuMC over 6 wks in the presence of rhSCF alone, or with LPS, PGN or LTA Figure 1
Cultures of CD34+ derived HuMC over 6 wks in the presence of rhSCF alone, or with LPS, PGN or LTA. (A-D): 
Total cell numbers – left; HuMC numbers- right. A) 100 ng/ml rhSCF; B) 100 ng/ml rhSCF and 10–1000 ng/ml LPS; C) 100 ng/
ml rhSCF and 10–1000 μg/ml PGN. Results are shown as the mean ± SEM of 3 separate experiments performed in duplicate; 
D) 100 ng/ml rhSCF and 0.1–10 μg/ml LTA. Results are shown as the mean ± SEM of 2 separate experiments performed in 
triplicate.BMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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HuMC was downregulated by the presence of LPS, while
PGN in the presence of 10 ng/ml rhSCF again inhibited
HuMC numbers. Due to the inhibition of HuMC growth
and development by TLR2 agonists PGN and LTA, the
remaining experiments focused on LPS and its HuMC
growth and survival enhancing effects.
FACS analysis of 8 wk FcεRI+/CD117+ HuMC cultured in rhSCF alone, with LPS or PGN Figure 2
FACS analysis of 8 wk FcεRI+/CD117+ HuMC cultured in rhSCF alone, with LPS or PGN. A) HuMC numbers fol-
lowing culture for 72 hr in 10 ng/ml rhSCF alone and with 100 ng/ml LPS or 10 μg/ml PGN. Results are shown as the means ± 
SEM of 3 separate experiments performed in duplicate; B and C) Representative dot plots of HuMC expression of FcεRI (ver-
tical axis) and CD117 (horizontal axis) following culture for 72 hr in 100 ng/ml (B) or 10 ng/ml (C) rhSCF (left-side plots), 
rhSCF and 100 ng/ml LPS (middle plots), and rhSCF and 10 μg/ml PGN (right-side plots) In C, CD117low (open arrows; insert 
R1 histogram) and CD117high (solid arrows; insert R2 histogram) are labeled. Representative dot plots are shown of n = 3 sep-
arate experiments performed in duplicate.BMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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Effect of LPS on 8 wk old HuMC β-hex, PGD2 and LTC4 
release in short-term cultures
We next proceeded to characterize the effect of LPS over
72 hr on HuMC, which had been in culture for 8 wks, as
to histamine content; and β-hex, PGD2 and LTC4 release.
In the presence of 10 ng/ml rhSCF, the addition of 100
ng/ml LPS increased the histamine content of HuMC over
72 hrs from a mean of 7.83 ± 2.33 pg/cell to 12.75 ± 1.94
pg/cell (n = 3, p < 0.05). We next assayed release and
found that the addition of 100 ng/ml LPS to 10 ng/ml
rhSCF over 72 hrs decreased β-hex release following FcεRI
crosslinking from 12.21 ± 0.31% to 3.56 ± 1.35% (n = 3,
p < 0.01). Following FcεRI crosslinking, LPS did not alter
PGD2 and LTC4 release (13.48 ± 0.52 ng/ml and 11.26 ±
4.75 ng/ml, respectively). Thus, the addition of LPS to
HuMC cultured over 72 hr with 10 ng/ml rhSCF reduced
% β-hex release, but had no effect on PGD2 and LTC4
release.
Effect of LPS on 8 wk HuMC protease expression and 
composition in short-term cultures
We next examined the effect of LPS on 8 wk old HuMC
protease expression and composition over 72 hrs. In the
presence of 10 ng/ml rhSCF and 100 ng/ml LPS, FACS
analysis showed significant increases in tryptase+, chy-
mase+, carboxypeptidase+, tryptase+/chymase+ and tryp-
tase+/carboxypeptidase+ HuMCs (n = 3, p < 0.01) (Fig.
3A, left) compared to cultures with 10 ng/ml rhSCF only.
This effect was not observed when cells were cultured in
100 ng/ml of rhSCF (Fig. 3A; compare right with left). As
shown in Figure 3B, live gate analysis of the CD117low
(region R1) and CD117high (region R2) HuMC subpopu-
lations, cultured in the presence of 10 ng/ml rhSCF with
and without 100 ng/ml LPS, determined that increases in
chymase and carboxypeptidase staining were detected
predominately for the CD117low(region R1) subpopula-
tion.
Effect of LPS and PGN on 8 wk old HuMC cytokine release 
and the effect of cytokines on protease expression
Since mature 8 wk HuMC cultures do not contain other
cell types, we next asked whether the effect of LPS on pro-
tease expression might be induced through endogenous
HuMC cytokine release. To this end, cell culture superna-
tants harvested from HuMC cultures following 72 hr incu-
bation with 10 or 100 ng/ml rhSCF alone, or with 100 ng/
ml LPS were assayed for the presence of IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12, IFN-γ, SCF and TNF-α. As shown
in Figure 4A, 100 ng/ml LPS induced HuMC to produce
IL-1β, IL-6, IL-8 and IL-12, with no differences noted
using 10 or 100 ng/ml rhSCF (n = 3, p < 0.05). No eleva-
tions in IL-2, IL-4, IL-10, IFN-γ and TNF-α were noted in
the presence of LPS. As expected, SCF was detected in cul-
tures containing SCF and LPS, but levels were not elevated
above those measured in cultures with SCF alone. In addi-
tion, no elevations in cytokines were noted in cultures to
which PGN had been added.
To determine if observed increases in tryptase, chymase
and carboxypeptidase expression could be explained on
the basis of endogenous IL-1β, IL-6, IL-8 and IL-12 release,
HuMC were cultured with rhSCF 10 or 100 ng/ml alone
or with rhIL-1β, rhIL-6, rhIL-8 and rhIL-12 individually or
as a four-cytokine mixture, using concentrations of
cytokines detected by immunoassay in the culture super-
natants (Fig. 4B). The combination of 10 ng/ml rhSCF
with either IL-1β or IL-6 gave rise to significant increases
in tryptase+, chymase+, tryptase+/chymase+ and tryp-
tase+/carboxypeptidase+ HuMCs, in contrast to rhIL-8 or
rhIL-12 which did not increase tryptase, chymase and car-
boxypeptidase expression (data not shown). No increases
in protease expression were observed in the presence of
100 ng/ml rhSCF with other cytokines. A combination of
10 ng/ml rhSCF with 150 pg/ml rhIL-1β, 25 pg/ml rhIL-6,
5000 pg/ml rhIL-8 and 25 pg/ml rhIL-12, cytokine con-
centrations detected in the cell cultures supernatant fol-
lowing 72 hr of incubation with 100 ng/ml LPS, gave rise
to increased tryptase+, chymase+, carboxypeptidase+ (n =
3, p < 0.01), tryptase+/chymase+ and tryptase+/carbox-
ypeptidase+ (n = 3, p < 0.05) HuMC numbers, reproduc-
ing the observed increases seen with 100 ng/ml LPS and
10 ng/ml SCF (Fig. 4B, left-sided graph). Furthermore,
this effect of LPS could be significantly reduced when
HuMC were cultured for 72 hr in the added presence of
0.5 μg/ml anti-IL-1β and 1.0 μg/ml anti-IL-6 antibodies
(Fig. 4B, right-sided graph). QPCR analysis of HuMC cells
showed an overall 8-fold increase in tryptase and 20-fold
increase in chymase expression, following stimulation for
72 hr with 10 ng/ml rhSCF, 150 pg/ml rhIL-1β, 25 pg/ml
rhIL-6, 5000 pg/ml rhIL-8 and 25 pg/ml rhIL-12 (Fig. 4C).
Similar increases in tryptase and chymase expression were
noted following stimulation for 72 hr with 10 ng/ml
rhSCF and 100 ng/ml LPS (Fig. 4C, right-sided graph).
Together, this data is consistent with the conclusion that
LPS stimulates HuMC in culture to release IL-1β, IL-6, IL-
8 and IL-12, and the overall net effect is to increase
CD117low HuMC production of tryptase, chymase and
carboxypeptidase.
Effect of LPS on 4–6 wk old WT and TLR4 KO BMMC 
protease mRNA expression in short-term culture
Since short-term exposure to LPS increased protease
expression in HuMC, we asked whether short-term expo-
sure to LPS could also effect the protease mRNA expres-
sion of BMMC from WT (C57BL/6) mice. Thus, BMMC
were first allowed to mature over 4–6 wks, washed and
cultured in either 3 or 30 ng/ml rmIL-3, 10 or 50 ng/ml
rmSCF alone and with 100 ng/ml LPS for 72 hr. BMMC
were then harvested and examined by QPCR for MMCP
mRNA expression. WT BMMC had constitutive mRNABMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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Figure 3
Tryptase, chymase and carboxypeptidase expression of 8 wk HuMC cultured in rhSCF alone and with 100 ng/
ml LPS; Live gate analysis of CD117low (R1 region) and CD117high (R2 region) cells. A) Left-sided graph – HuMC 
numbers expressing tryptase, chymase, and carboxypeptidase following culture for 72 hr in 10 ng/ml rhSCF alone, and with 100 
ng/ml LPS. For 10 ng/ml rhSCF alone, the mean ± SEM of percentages of protease positive HuMC are: tryptase 88.51 ± 5.30%, 
chymase 91.34 ± 1.62%, carboxypeptidase 91.53 ± 1.20%, tryptase/chymase 83.75 ± 4.61% and tryptase/carboxypeptidase 
87.32 ± 4.90%. For 10 ng/ml rhSCF and LPS, the mean ± SEM of percentages of protease positive HuMC cells are: tryptase 
92.50 ± 2.32%, chymase 96.30 ± 0.75%, carboxypeptidase 94.43 ± 4.21%, tryptase/chymase 92.33 ± 3.85%, and tryptase/car-
boxypeptidase 90.50 ± 2.30%. Right-sided graph – 100 ng/ml rhSCF alone, and with 100 ng/ml LPS. For 100 ng/ml rhSCF alone, 
the mean ± SEM of percentages of protease positive HuMC are: tryptase 94.56 ± 2.30%, chymase 93.30 ± 1.38%, carboxypepti-
dase 88.50 ± 3.21%, tryptase/chymase 88.70 ± 5.41%, and tryptase/carboxypeptidase 88.55 ± 3.83%. For 100 ng/ml rhSCF and 
LPS, the mean ± SEM of percentages of protease positive HuMC are: tryptase 92.57 ± 3.30%, chymase 95.33 ± 0.85%, carbox-
ypeptidase 89.81 ± 3.90%, tryptase/chymase 93.63 ± 3.25%, and tryptase/carboxypeptidase 89.50 ± 5.42%. Results are shown 
as the mean ± SEM of 3 separate experiments performed in duplicate; B) Representative dot plots and histograms of CD117low 
(R1 region) and CD117high (R2 region) cells analyzed for FcεRI, CD117, tryptase, chymase and carboxypeptidase expression 
during culture in 10 ng/ml rhSCF alone and with 100 ng/ml LPS (as seen in Figure A, left). In the histograms, horizontal axis rep-
resents PE or PE5.5-conjugated markers analyzed; vertical axis represents total cell numbers analyzed. Cultures with 10 ng/ml 
rhSCF alone are shown by the shaded areas. Representative dot plots and histograms are shown of n = 3 separate experiments 
performed in duplicate.BMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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expression for the proteases MMCP-4, -5, -6 and CPA3
when cultured in either rmIL-3 (3–30 ng/ml) or rmSCF
(10–50 ng/ml) for 72 hr (data not shown). As shown in
Figure 5, following the addition of LPS for 72 hr, an upreg-
ulation in MMCP-1, MMCP-2 and MMCP-4 mRNA
expression was observed in the presence of either rmIL3
(3 ng/ml) (Fig. 5A) or in the presence of rmSCF (10 ng/
ml) (Fig. 5B). A similar pattern of MMCP upregulation
was also observed at the higher concentrations of rmIL3
(30 ng/ml) or rmSCF (50 ng/ml) in the presence of LPS
(data not shown). Since TLR4 deficient mice are hypore-
sponsive to lipopolysaccharide [8], and to determine if
upregulated MMCP levels by LPS were mediated by TLR4,
we obtained BMMC from WT C3H/HeOuJ and TLR4 KO
C3H/HeJ mice and exposed them to low concentrations
of cytokine in combination with LPS. As can be seen, in
the presence of either rmIL-3 (3 ng/ml) (Fig. 5C) or
rmSCF (10 ng/ml) (Fig. 5D), WT BMMC from C3H/
HeOuJ mice had a similar MMCP mRNA profile in
response to LPS as WT BMMC from C57BL/6 mice. How-
ever, in contrast with C3H/HeOuJ, BMMC cultured from
C3H/HeJ mice and incubated with mIL-3 (3 ng/ml) (Fig.
5C; compare with 5A), or rmSCF (10 ng/ml) (Fig. 5D;
compare with 5B) had reduced MMCP-1, MMCP-2 and
MMCP-4 mRNA expression following incubation with
LPS. BMMC from both WT and TLR2 KO mice were also
cultured in the presence of rmIL-3 (3 ng/ml) or rmSCF (10
ng/ml) with PGN or LTA for 72 hr, and examined for any
effect on protease mRNA expression. As shown in Figures
5E–H, neither TLR2 ligand affected MMCP expression in
WT or TLR2 KO mice. Taken together these data suggest
that LPS, but not the TLR2 ligands PGN or LTA, induce the
upregulation of MMCP-1, -2 and -4 mRNA expression in
BMMC through cytokines which are produced by mast
cell activation through TLR4.
Discussion
In this report, we demonstrate that LPS and PGN have
very different and specific effects on progenitor and
mature HuMC. These observations are relevant, since
HuMC maturation may occur in proximity to tissues such
as the lung and gastrointestinal mucosa that interface with
the external environment, where HuMC progenitors and
their mature counterparts may variably be exposed to bac-
terial-derived products over time. It has been shown, for
example, that inhalation of aerosolized LPS exacerbates
allergic airway inflammation in the mouse experimental
asthma model through TLR4-mediated mast cell activa-
tion and promotion of TH2 responses [9]. Cell transfer
experiments using TLR4 KO mast cells confirmed that the
effect of LPS is mediated through TLR4 on mast cells, con-
sistent with our data. We also found that HuMCs in the
presence of LPS synthesized de novo IL-1β and IL-12, in
addition to IL-6 and IL-8, which is consistent with the
induction of TH1 effector responses reported for mouse
dendritic cell (DC) cultures [10]. If the hypothesis put for-
ward that, under experimental conditions, toll-mediated
events facilitate the generation of TH1 responses [10], then
mouse and human in vitro mast cell data are in agreement,
and in vivo inhalation of aerosolized LPS might induce
both HuMC and DC to produce increased cytokine levels
that lead to the promotion of TH1-skewed responses. The
net effect of these TH1 responses in combination with LPS-
induced TH2 responses would determine the overall
extent of allergic airway inflammation.
We thus examined CD34+-derived HuMC progenitors
over 6 wks (long-term cultures) and 8 wk mature HuMC
over 72 hr (short-term cultures) for the effect of LPS, PGN
and LTA on cell numbers; and CD117, FcεRI, cytokine,
tryptase, chymase and carboxypeptidase expression. In
continuous culture over 6 wks, LPS had little or no effect
on HuMC numbers, while PGN led to a decrease in
HuMC numbers at all concentrations (Fig. 1). LTA,
another TLR2 agonist, also decreased HuMC numbers at
the highest concentrations. LPS, but not PGN, led to small
increases in CD117, tryptase and chymase expression
compared with rhSCF alone, while decreasing FcεRI
expression (data not shown).
These differential effects of LPS and PGN became more
evident when mature 8 wk HuMC were used in short-term
cultures. When 8 wk HuMC, originating from CD34+ cells
in rhSCF, were cultured with PGN and 10 ng/ml rhSCF for
72 hr, PGN reduced HuMC numbers below those
observed with 10 ng/ml rhSCF alone. PGN had no effect
on HuMC numbers when 100 ng/ml rhSCF was used. LPS
somewhat enhanced HuMC numbers in the presence of
10 ng/ml rhSCF. FcεRI expression was again reduced in
cultures containing either 10 or 100 ng/ml rhSCF and LPS
(Fig. 2), consistent with the observation that the LTA, fol-
lowing ligation with TLR2, reduced surface expression of
FcεRI in isolated human pulmonary mast cells [11]. In the
presence of 10 ng/ml rhSCF, the reduction in FcεRI expres-
sion could be seen to affect two CD117 subpopulations:
CD117low and CD117high HuMCs (Fig. 2B). The MFI of the
CD117high cells increased a log-fold higher, suggesting
that 100 ng/ml of rhSCF suppressed CD117 expression on
HuMC, consistent with other reports [12]. In the presence
of LPS and 10 ng/ml, but not 100 ng/ml of rhSCF, tryptase
positive HuMC co-expressing chymase and carboxypepti-
dase increased (Fig. 3A), and live gate analysis showed
that increases in tryptase, chymase and carboxypeptidase
occurred predominately in the CD117low subpopulation
(Fig. 3B). These data therefore demonstrate that short-
term exposure of mature HuMC to varying concentrations
of rhSCF alters CD117 expression [12], and protease
expression; and that these effects are modulated by LPS.
Of note is that 100 ng/ml rhSCF that we and others use forBMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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Figure 4
Immunoassay of cytokine release and cytokine effect on tryptase, chymase, and carboxypeptidase expression 
of 8 wk HuMC by FACS and QPCR. Effect of rhIL-1β and rhIL-6 blocking antibodies. A) Immunoassay for the pres-
ence of IL-1β, IL-6, IL-8, IL-12 and SCF in supernatants of 8 wk HuMC treated for 72 hr with rhSCF, rhSCF and LPS, and rhSCF 
and PGN; B) Left-sided graph – HuMC numbers expressing tryptase, chymase, and carboxypeptidase following 72 hr in culture 
with 10 ng/ml rhSCF alone, and with 150 pg/ml rhIL1-β, 25 pg/ml rhIL-6, 5000 pg/ml rhIL-8, and 25 pg/ml rhIL-12. For 10 ng/ml 
rhSCF alone, the mean ± SEM of percentages of protease positive HuMC are: tryptase 91.50 ± 3.13%, chymase 92.20 ± 3.11%, 
carboxypeptidase 95.73 ± 1.86%, tryptase/chymase 87.32 ± 3.76% and tryptase/carboxypeptidase 85.70 ± 4.77%. For 10 ng/ml 
rhSCF and rhIL1-β, rhIL-6, rhIL-8, and rhIL-12, the mean ± SEM of percentages of protease positive HuMC are: tryptase 94.99 
± 0.83%, chymase 97.23 ± 0.35%, carboxypeptidase 97.62 ± 0.50%, tryptase/chymase 89.93 ± 3.87% and tryptase/carboxypepti-
dase 89.80 ± 4.23%. Results are shown as the mean ± SEM of 3 separate experiments performed in duplicate. Right-sided graph 
– HuMC numbers expressing tryptase, chymase, and carboxypeptidase following 72 hr in culture with 10 ng/ml rhSCF and 100 
ng/ml LPS, and with 0.5 μg/ml anti-rhIL-1β and 1 μg/ml anti-rhIL-6. Goat blocking antibodies are matched with goat isotype IgG 
control. For 10 ng/ml rhSCF and LPS, the mean ± SEM of percentages of protease positive HuMC are: tryptase 92.30 ± 1.30%, 
chymase 98.22 ± 0.35%, carboxypeptidase 95.53 ± 1.22%, tryptase/chymase 91.40 ± 2.77%, and tryptase/carboxypeptidase 
91.43 ± 1.91%. For 10 ng/ml rhSCF, LPS, anti-rhIL-1β and anti-rhIL-6, the mean ± SEM of percentages of protease positive 
HuMC are: tryptase 90.60 ± 1.37%, chymase 94.71 ± 0.45%, carboxypeptidase 92.12 ± 1.22%, tryptase/chymase 88.30 ± 2.31%, 
and tryptase/carboxypeptidase 87.11 ± 3.05%. Results are shown as the mean ± SEM of 2 separate experiments performed in 
duplicate. C) Left-sided graph – QPCR for tryptase and chymase expression of HuMC cultured with rhSCF alone, and with IL-
1β, IL-6, IL-8 and IL-12; Right-sided graph – QPCR for tryptase and chymase expression of HuMC cultured with rhSCF alone, 
and with LPS. Results are shown as the fold increase over rhSCF alone, and are the mean ± SEM of n = 3 separate experiments 
performed in triplicate.BMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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optimal HuMC in vitro growth may mask the upregula-
tory effects of LPS, when LPS is added to cultures.
It has been reported that activation of murine mast
[13,14] and dendritic [15] cells through TLRs augments
production of inflammatory cytokines, and that cytokines
can influence human mast cell protease expression
[16,17]. To determine whether LPS-driven short-term cul-
tures induced HuMC-derived cytokine production which
in turn could influence cell survival as well as changes in
surface receptor and protease expression, we assayed
short-term cultures and found, as noted above, significant
levels of IL-1β, IL-6, IL-8 and IL-12 in LPS-driven, but not
PGN-driven, cultures. Furthermore, we were able to repro-
duce the effects of LPS on HuMC by culturing these cells
in 10 ng/ml rhSCF and immunoassay-detected concentra-
tions of IL-1β, IL-6, IL-8 and IL-12 (Fig. 4B). The combi-
nation of 10 ng/ml rhSCF with either IL-1β or IL-6, but
not IL-8 or IL-12, also reproduced the LPS observed effects
in short-term cultures. Thus, one possible mechanism of
action of LPS is to stimulate production of mature HuMC-
derived IL-1β and IL-6, which together promote HuMC
survival, alter HuMC FcεRI and protease expression, and
together with IL-12 direct HuMC involvement in resolv-
ing innate immunity and promoting acquired immune
responses. This transition from innate to acquired immu-
nity involves the resolution of an inflammatory event,
and as demonstrated in mouse models, IL-6 is involved in
reducing bacteria-induced inflammation [18-20]. In addi-
tion, although IL-8 was not shown to affect HuMC sur-
vival, surface receptor and protease expression, IL-8
production by HuMC might in part explain how LPS can
promote neutrophil influx into inflammatory sites and
promote host defense mechanisms.
The conclusion that LPS upregulates HuMC protease
expression and composition were further supported using
BMMC from WT and TLR4 KO mice (Fig. 5). It is known
that exposure of WT BMMC to rmIL3 and rmSCF alters the
protease composition of these cells [21]. Following expo-
sure of WT BMMC to reduced concentrations of rmIL-3 or
rmSCF in the presence of LPS an increase in mRNA for the
MMCP-1, -2 and -4 was observed. BMMC from TLR4 KO
mice, following stimulation with LPS, failed to show any
alteration in MMCP-1, MMCP-2, and MMCP-4 mRNA
expression compared with WT controls. These findings
demonstrate that the differential mRNA expression of
MMCP depends on the presence and concentration of
rmIL-3 or rmSCF used to culture BMMC, and that the
MMCP mRNA expression of BMMC can be influenced by
LPS ligation with TLR4, an effect which is eliminated in
the absence of a functional TLR4 receptor. MMCP-1
mRNA expression in mucosal mast cells of Trichinella spi-
ralis-infected mice can similarly be influenced by IL-10
[22]. Furthermore, MMCP-1, MMCP-2 and MMCP-4 are
chymases, and MMCP-4 most probably represents the
murine homolog of human chymase [23]. In addition,
the observation that TLR2 ligands PGN and LTA had no
effect on MMCP mRNA expression from WT and TLR2
KO-derived BMMC appears to be consistent with the
observation in HuMC (Figure 4) that LPS, but not PGN,
increases HuMC numbers and protease expression, and
may be related to the LPS-induced increase in IL-1β and
IL-6.
The upregulation of human chymase and carboxypepti-
dase by LPS may be another means by which mast cells
participate in endotoxin-driven alteration in TH1 and TH2
responses. Mast cell-derived chymase and carboxypepti-
dase are involved in resistance to toxic endogenous or
exogenous peptides such as endothelin-1 [24] and ven-
oms [25] respectively; thus, their induction may counter-
balance the effect of tryptase which is known to increase T
cell-derived IL-13 and airway hyper-responsiveness [26].
Conclusion
Taken together, these data demonstrate that LPS can alter
HuMC numbers, influence cytokine and protease expres-
sion and composition, and that the effect of LPS is best
observed when reduced concentrations of rhSCF are used,
as may occur in tissues. These data further support the
idea that the appearance of LPS during a gram negative
bacterial infection, in the presence of tissue concentra-
tions of SCF, may induce tissue mast cells to express a
unique composition of proteases beneficial for control-
ling and eliminating this particular infection. In other
infections or clinical states having higher concentrations
of other cytokines and/or the presence of other mediators,
tissue mast cell progenitors may differentially develop
and express specific surface receptors and proteases which
enable these mast cells to more effectively participate in
innate immune responses.
Methods
CD34+ immunoselection
Peripheral blood (PB) mononuclear cells collected by leu-
kapheresis were obtained from normal volunteers follow-
ing informed consent [1]. CD34+ progenitor cells were
enriched to 95–99% by positive immunomagnetic selec-
tion or using commercially available affinity columns.
HuMC long-term and short-term cultures
Long-term cultures
Peripheral blood CD34+ cells were placed at a concentra-
tion of 5 × 104 cells/ml in serum-free media (SFM) (Stem-
Pro-34 SFM; Life Technologies, Grand Island, NY)
supplemented with 2 mM L-glutamine, 100 IU/ml peni-
cillin, 50 μg/ml streptomycin (complete SFM) and 100
ng/ml recombinant human stem cell factor (rhSCF)
(Peprotech, Rocky Hill, NJ) alone or in combination withBMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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Protease mRNA expression by WT, TLR4 KO and TLR2 KO BMMC in the presence of LPS, PGN or LTA and either rmIL-3 or  rmSCF Figure 5
Protease mRNA expression by WT, TLR4 KO and TLR2 KO BMMC in the presence of LPS, PGN or LTA and 
either rmIL-3 or rmSCF. MMCP-1 [1], MMCP-2 [2], MMCP-4 [4], MMCP-5 [5], MMCP-6 [6] and carboxypeptidase A 
(CPA3) were analyzed by real-time PCR from 4–6 wk WT (C57BL/6) BMMC (A-B), WT (C3H/HeOuJ), TLR4 KO (C3H/HeJ) 
BMMC (C-D), and WT, TLR2 KO BMMC (E-H). BMMC were cultured for 72 hr with either 3 ng/ml rmIL-3 (A, C, E, G) or 10 
ng/ml rmSCF (B, D, F, H) in the absence or presence of 100 ng/ml LPS, 10 μg/ml PGN or 1 μg/ml LTA. The effect of LPS, PGN 
or LTA on protease mRNA expression was determined by calculating the fold increase compared to untreated control 
(C57BL/6 or C3H/HeOuJ) samples. Results shown are mean ± SEM, n = 4 in triplicate for WT BMMC (A-B), n = 3 in triplicate 
for WT and TLR4 KO BMMC (C-D), and n = 2 in triplicate for WT and TLR2 KO BMMC (E-H).BMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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either 10–1000 ng/ml LPS (Sigma-Aldrich, St. Louis,
MO), 10–1000 μg/ml PGN (Fluka, Ronkonkoma, NY) or
0.1–10 μg/ml LTA (Invivogen, San Diego, CA). Heat inac-
tivated human serum was added to cultures containing
LPS. Cells were counted and stained weekly with Kimura's
stain and tested for tryptase positivity to determine total
cell and HuMC numbers as described [1,27]. Kimura's
and tryptase staining of HuMC did not differ by greater
than 5%. Cytokines and TLR ligands were replaced
weekly. Short term cultures: Eight wk HuMC were cultured
in 100 ng/ml rhSCF, washed and then incubated for 72 hr
with either 10 or 100 ng/ml rhSCF alone, or in combina-
tion with either 100 ng/ml LPS or 10 μg/ml PGN. In some
experiments, 8 wk HuMC were cultured with cytokines
(IL-1β, IL-6, IL-8, or IL-12) alone or in combination
(Peprotech, Rocky Hill, NJ), in addition to blocking anti-
bodies for IL-1β (R&D, Minneapolis, MN) and IL-6
(Peprotech, Rocky Hill, NJ). Cells were harvested and pre-
pared for flow cytometry, mediator and cytokine release,
and real-time PCR for analysis of protease expression.
BMMC from WT and TLR4 KO mice
WT (C57BL/6, C3H/HeOuJ), TLR4 KO (C3H/HeJ) and
TLR2 KO mice (< 6 months old, 20 g) were obtained from
Jackson Laboratories (Bar Harbor, ME). Mouse bone mar-
row-derived mast cells (BMMC) were cultured from fem-
oral marrow cells in RPMI 1640 medium supplemented
with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 25 mM HEPES, 1.0 mM sodium pyruvate, non-essen-
tial amino acids, 0.0035% 2-mercaptoethanol (complete
RPMI) and 30 ng/ml recombinant mouse (rm) IL-3
(Peprotech, Rocky Hill, NJ). In all experiments, 4–6 wk
old BMMC were harvested, washed in complete RPMI,
and incubated with 10–50 ng/ml rmSCF (Peprotech,
Rocky Hill, NJ), or 3–30 ng/ml rmIL-3 alone or in combi-
nation with 100 ng/ml LPS, 10 μg/ml PGN or 1 μg/ml
LTA.
β-hexosaminidase (β-hex) release
HuMC were sensitized overnight with 100 ng/ml of bioti-
nylated human IgE (biotIgE). Cells were then washed to
remove excess biotIgE, and crosslinked using streptavidin
(SA) (BD PharMingen, San Diego, CA) as previously
described [28]. β-hex was reported as % release. %β-hex
release after 72 hr was calculated as net relative to the non-
activated cells in the presence of SCF+LPS and compared
with HuMC treated with SCF alone.
Histamine, LTC4 and PGD2 assay
Cellular histamine content and LTC4 and PGD2 release
were examined in duplicate using 1,000–10,000 HuMC
washed in HEPES with 0.04% BSA. Histamine content
was analyzed with a commercial histamine ELISA Kit
(Immunotech, Cedex, France) and reported as pg/cell.
LTC4  and PGD2release were analyzed by competitive
enzyme immunoassay (EIA) (Cayman Chemicals, Ann
Arbor, MI) and reported as ng/ml.
Flow cytometric analysis
HuMC surface marker and intracytoplasmic staining was
performed using a modified approach for mononuclear
cells [29]. Briefly, cells were incubated sequentially with
one or more of the following conjugated antibodies: 5 μg/
ml biotIgE; 2.5 μg/ml R-phycoerythrin (PE) (1 mg/ml;
Ancell, Bayport, MN) or allophycocyanine (APC)-conju-
gated CD117 (Becton-Dickinson, San Jose, CA), 2.0 μg/
ml PE5.5 (Caltag/Invitrogen, Carlsbad, CA) or 2.5 μg/ml
APC-conjugated streptavidin (SA) (0.2 mg/ml; BD
PharMingen, San Diego, CA) per final volume of 50 μl
containing 20,000–50,000 nucleated cells). PE conju-
gated annexin V was used to determine apoptosis (Detec-
tion Kit I; BD PharMingen, San Diego, Ca). In all
experiments, 10,000–20,000 cell events were analyzed.
Cell analysis was performed using a FACScan and Cel-
lQuest software (Becton Dickinson, San Jose, CA).
Intracytoplasmic staining for tryptase, chymase and 
carboxypeptidase
HuMCs were fixed and permeabilized using 4% parafor-
maldehyde and 1 × PBS with 0.1% saponin and stained
for tryptase, chymase and carboxypeptidase as described
[7,29]. For tryptase/chymase or tryptase/carboxypeptidase
staining, cells were first stained for tryptase using 3 μg/mL
mouse antihuman tryptase (Clone G3, 1.14 mg/mL,
Chemicon, Temecula, CA) and 5.0 μg/ml PE-conjugated
goat antimouse IgG (0.5 mg/ml, Southern Biotechnology,
Birmingham, AL). Cells were washed and incubated with
either 3 μg/mL biotinylated mouse antihuman chymase
(Clone B7, 3 mg/mL, Chemicon, Temecula, CA) or 3 μg/
ml biotinylated mouse antihuman carboxypeptidase
(kind gift of Dr. Andrew Walls, University of Southamp-
ton, UK). Cells were washed and incubated with 2.5 μg/
ml APC-conjugated SA. Cell analysis was performed using
20,000–50,000 nucleated cells per final volume of 50 μl.
In all experiments, 10,000–20,000 cell events were ana-
lyzed using a FACScan and CellQuest software. In all
experiments, the numbers of HuMC positive for one or
more proteases was calculated by multiplying the total
number of cells examined in culture by the percentage of
gated, single or dual protease positive cells determined
using flow cytometry.
Human cytokine immunoassay
Quantitative enzyme immunoassays for IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12 (measured as the heterodimer IL-
12p70), IFN-γ, SCF and TNF-α in cell-free culture superna-
tants were performed using the following commercial
cytometric bead array (CBA) kits; Human Chemokine Kit
and Human Th1/Th2 Cytokine Kit II (BD Biosciences, San
Jose, CA) and analyzed on a FACSArray Bioanalyzer. TheBMC Immunology 2008, 9:45 http://www.biomedcentral.com/1471-2172/9/45
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minimum detection levels for the chemokines and
cytokines are IL-1β, 7.2 pg/mL, IL-2, 2.6 pg/mL, IL-4, 2.6
pg/mL, IL-6, 3.0 pg/mL, IL-8, 0.2 pg/mL, IL-10, 2.8 pg/mL,
IL-12, 1.9 pg/mL, IFN-γ, 7.1 pg/mL and TNF, 2.8 pg/mL.
Real-time PCR analysis for HuMC and BMMC protease 
mRNA expression
Total RNA was isolated from each preparation using the
RNeasy Mini Kit (Qiagen, Valencia, CA). For HuMC, one
microgram of total cellular RNA was treated for genomic
DNA contamination and reverse transcribed using Invit-
rogen Reverse Transcription reagents and oligo dT. Gene
expression was analyzed using real-time PCR on an
ABI7500 SDS system. One hundred ng of cDNA was used
in each quantitative PCR assay, and tryptase and chymase
primer sets (Qiagen, Valencia, CA) for PCR amplifications
were designed using Primer Express software (Perk-
inElmer, Shelton, CT). All reactions were performed in
triplicate for 40 cycles. Samples were normalized using
the geometric mean of GAPDH15 and data are reported as
the ratio of treated cells/untreated control cells. Different
stocks of cDNA were used for all amplifications to deter-
mine the relative quantities across multiple runs.
For BMMCs, two micrograms of total cellular RNA was
treated for genomic DNA contamination and reverse tran-
scribed using the Qiagen genomic DNA wipeout buffer
and reverse transcription reagents. For each quantitative
PCR assay, fifty ng of cDNA was mixed with PCR master-
mix containing primer sets (Qiagen, Valencia, CA) for
mouse mast cell proteases (MMCP)-1, MMCP-2, MMCP-
4, MMCP-5, MMCP-6, carboxypeptidase A (CPA3) or the
housekeeping gene β-actin. As a control, RNA which had
not being reverse transcribed to cDNA was used in some
PCR reactions. All reactions were performed in triplicate
for 40 cycles, and gene expression analyzed using the Real-
Time PCR cycler ABI PRISM 7700 (Applied Biosystems,
Foster City, CA). The relative fold expression levels of
MMCPs between treatment groups was calculated as fol-
lows; for each sample the threshold cycle (Ct) was deter-
mined and normalized to β-actin (ΔCt). The ΔCt of
treated cells was then subtracted from untreated control
cells (ΔΔCt) and the relative fold expression was calcu-
lated using the formula 2ΔΔCt. cDNA stocks were taken
from 3 different cultures of BMMC to determine relative
quantities across multiple runs.
Statistical Analysis
Statistical analysis of data was performed using Student's
paired t-Test. Significant differences of the means were
represented as either * (p < 0.05), ** (p < 0.01) or *** (p
< 0.001).
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